CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 801–900 of 1,001
Ling, D., Li, N., Pan, X., Gao, W., Hao, L. P., Tian, Q., Li, J., Cheng, Q., Tang, L., Zhang, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114640 · Cited by 6
Advances in immune cell-based therapeutic agents for the treatment of inflammation-related diseases
Yang, Y., Liu, J., Liu, J., Wei, S., Kong, X., Mu, W., Liu, Y., & Zhang, N. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.013 · Cited by 10
Intrapericardial delivery of FAP-CAR-T cells via a ROS-responsive hydrogel to treat cardiac fibrosis
Cao, B., Liu, M., Anwaier, S., Long, X. L., You, T., He, Z., Su, H., Zhang, X., Wang, J., Huang, H., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114697 · Cited by 7
T cell-inspired therapeutic delivery platforms: From nanomedicines to cell therapy
Jan, N., Shah, H., Khan, S., Khan, N. U., Li, Y., Zhang, X., & Shi, G. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.102909 · Cited by 8
On the road to in vivo CAR-T success: Comparing promising viral and non-viral vectors
de la Mota, S., Suchet, L., van Wijk, M., Stibbs, D. J., Couto, P. S., & Rafiq, Q. A. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108907 · Cited by 6
The in vivo revolution in CAR-T therapy medicinal products: challenges and regulatory prospects
Lü, J., Cui, J., Dong, J., Yan, L., Wang, X., Zhou, D., Lu, S., & Wei, W. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02633-4 · Cited by 11
CAR-T Therapy in HIV: Pioneering Advances and Navigating Challenges
Wang, X., Liu, J., Hao, F., Ajavavarakula, T., & Shi, X. (2024) · Infectious Diseases & Immunity · doi:10.1097/id9.0000000000000129 · Cited by 7
Genetically engineered biomimetic ATP-responsive nanozyme for the treatment of cardiac fibrosis
Zhao, X., Qin, Y., Li, B., Wang, Y., Liu, J., Wang, B., Zhao, J., Yin, J., Zhang, L., Li, J., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-03083-2 · Cited by 11
Immune Cell Dynamics in Heart Failure: Implicated Mechanisms and Therapeutic Targets
Li, G., He, W., & Wang, D. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15238 · Cited by 8
Wu, M., Li, J., Xu, Y., Lv, S., Wang, G., Huang, Y., Tao, Y., Ju, C., & Zhang, C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113779 · Cited by 7
mRNA lipid nanoparticles in CAR-T therapy: a novel strategy to improve efficacy
Zhao, Z., Li, M., Zheng, X., Gao, P., Huang, C., Yu, Q., Jin, L., Zhang, L., Zhu, D., & Li, F. (2025) · Nanotechnology · doi:10.1088/1361-6528/add482 · Cited by 7
In-vivo-targeted gene delivery using adenovirus-antibody site-specific covalent conjugates
Rice-Boucher, P. J., Kashentseva, E. A., Dmitriev, I. P., Guo, H., Tremblay, J. M., Shoemaker, C. B., Curiel, D. T., & Lu, Z. H. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101497 · Cited by 8
RNA-ssisting immunity to heal the heart: a new frontier in therapeutics
Rurik, J. G., Phu, C. L., Mustroph, J., & Buggert, M. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000116 · Cited by 6
Self-citationZhang, G., Tu, J., Zhang, Y., He, J., Peng, G., Fan, Q., Zhang, Y., Zhang, M., Tan, H., Xu, Y., et al. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102620 · Cited by 7
Liao, Q., Mao, Y., Feng, M., Zheng, N., Ding, X., Zhang, X., Wang, Z., & Xu, J. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00050-2 · Cited by 6
Scott, T. A., Soemardy, C., Ray, R. M., & Morris, K. V. (2023) · NAR Cancer · doi:10.1093/narcan/zcac046 · Cited by 6
RNA-Based Therapeutic Technology
Mashima, R., Takada, S., & Miyamoto, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242015230 · Cited by 6
Chimeric antigen receptors: “CARs” in the fast lane for rheumatology
Johnson, N. M., & Koumpouras, F. (2024) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000001012 · Cited by 6
Current and Emerging Radiotracers in Molecular Cardiovascular Imaging
Joshi, S. S., Geers, J., Gimelli, A., Hyafil, F., Habib, G., Erba, P. A., Gheysens, O. S., Glaudemans, A. W. J. M., Newby, D. E., Slart, R. H. J. A., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.123.016323 · Cited by 6
Tsioulos, G., Vallianou, N. G., Skourtis, A., Dalamaga, Μ., Kotsi, E., Kargioti, S., Adamidis, N., Karampela, Ι., Mourouzis, I. S., & Kounatidis, D. C. (2024) · Biomolecules · doi:10.3390/biom14121637 · Cited by 6
Characterization of lipid nanoparticles using macro mass photometry: Insights into size and mass
Wu, J., Zhang, Y., Wu, Z., Townsend, J. A., Crooks, I., Watt, B., Baik, A. D., Cygnar, K. D., Qiu, H., & Li, N. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.343944 · Cited by 7
Interfacial T cell engineering
Alapan, Y., & Thomas, S. N. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00316-3 · Cited by 8
Xu, E. J. K., Smith, B. E., Alberto, W. D. C., Walsh, M. J., Lim, B. S., Hoffman, M. T., Li, Q., Barreiro, A. E., Finburgh, E. N., Dong, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adv2331 · Cited by 6
Salehi-Shadkami, H., Sedghi, M., Tavoosi, S., Alimohammadi, M., Alimohammadi, R., Barkhordar, M., Mofayezi, A., Modaresi, M. S., Vaezi, M., Dehghanizadeh, S., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103563 · Cited by 9
Direct cardiac reprogramming: Toward the era of multi-omics analysis
Liu, M., Liu, J., Zhang, T., & Wang, L. (2022) · Cell Insight · doi:10.1016/j.cellin.2022.100058 · Cited by 6
Pascolo, S. (2023) · European Journal of Immunology · doi:10.1002/eji.202249941 · Cited by 6
A Theranostic Approach for CAR-T Cell Therapy
Weber, W., Varasteh, Z., Fritschle, K., & Morath, V. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2565 · Cited by 6
Antigen-specific T cell immunotherapy by in vivo mRNA deliveryPreprint
Su, F., Siebart, J. C., Chan, C. S., Wang, M. Y., Yao, X., Trenkle, A. S., Sivakumar, A., Su, M., Harandi, R., Shahrawat, N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.29.620946 · Cited by 9
Chen, P., Raghunandan, R., Morrow, J. S., & Katz, S. G. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.04.002 · Cited by 6
Li, J., & Foged, C. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2409142 · Cited by 6
Kim, B., Subraveti, S. N., Liu, J. X., Nayagam, S. K., Merghoub, S., Caggiano, N. J., Amelemah, D. F., Jiang, T., Bizmark, N., Conway, J. M., et al. (2024) · ACS Applied Bio Materials · doi:10.1021/acsabm.4c01176 · Cited by 5
Is there a place for engineered immune cell therapies in autoimmune diseases?
Perico, L., Casiraghi, F., Benigni, A., & Remuzzi, G. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.011 · Cited by 5
Strategies for Altering Delivery Technologies to Optimize CAR Therapy
Cao, L., Liu, Y., & Lin, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073206 · Cited by 6
Mao, Y.-A., Wang, R., Shi, X., Jin, Y., Pan, Z., Chatterjee, E., Li, G., Chen, X., Wang, H., Jiang, J., et al. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10660-9 · Cited by 5
PCR-generated DNA templates enable efficient, rapid, and cost-effective mRNA synthesis
Kumar, N., Hazell, N. C., Bei, J., Nguyen, T. K., & Hu, H. (2025) · Methods · doi:10.1016/j.ymeth.2025.08.007 · Cited by 5
Kolibius, J., Weiss, F., Freitag, P. C., & Plückthun, A. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101582 · Cited by 5
Fibroblast Activation Protein‐Targeted CAR‐T Cells Induce Apoptosis in Murine Cardiac Myofibroblasts
Li, H., Zheng, Q., Jiang, Y., Yang, L., Li, S., Yang, P. C., Yin, G., & Sun, L. (2025) · Cardiovascular Therapeutics · doi:10.1155/cdr/7230505 · Cited by 7
CAR-T cells targeting CD19 for the treatment of ANCA vasculitis
Lodka, D., & Schreiber, A. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf290 · Cited by 5
Translatable circular RNAs: Mechanism, function and clinical application
Song, Z., Zhou, M., Lin, J., You, J., & Huang, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.149185 · Cited by 8
Wei, C., Shan, X., Huang, Y., Ma, B., Zhao, Z., Fang, Y., Bai, C., Zhang, Z., Zhao, P., Zhang, H., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c16886 · Cited by 5
mRNA medicine for cardiovascular disease
Zhou, Z., Chen, W., Yu, H., Tabas, I. A., Foo, R., & Tao, W. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00804-8 · Cited by 6
Akkineni, S., Gulani, M. A., Kouzi, S. A., D’Souza, M. J., & Uddin, M. N. (2026) · Pharmaceuticals · doi:10.3390/ph19050663 · Cited by 6
Circadian engineering of in vivo CAR T cell therapy for precision oncology
Bautista, J., Echeverría, C. E., Rodríguez-Marcano, M. G., & López-Cortés, A. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01464-4 · Cited by 6
Yadav, V., Yadav, P., Mallappa, S., & Neeli, P. (2026) · Biomedicines · doi:10.3390/biomedicines14061276 · Cited by 7
Cardiac-targeted delivery of advanced medical therapies for heart disease
Liu, X., Yan, M., Lu, S., & Hausenloy, D. J. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag432 · Cited by 4
Nanotechnology-mediated precision delivery of mRNA
Deng, H., Li, L., Zhao, C., Wang, Z., Xiao, Y., Huang, P., Siegwart, D. J., & Chen, X. S. (2026) · Nature Materials · doi:10.1038/s41563-026-02623-5 · Cited by 7
Self-citationCAR T cell therapy beyond cancer: current status, challenges and future prospects
Upadhyay, S., Cho, S., Upmanyu, K., & Gabr, M. T. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02873-4 · Cited by 6
An inherent T cell-activating mRNA delivery carrier for in vivo CAR T generation
Cao, Q., Yao, Y., Zheng, W., Liu, H., Jiang, M., Xie, D., Zhang, S., Su, P., Yuan, H., Chen, X. S., et al. (2026) · Nature Materials · doi:10.1038/s41563-026-02675-7 · Cited by 7
Your Heart Function Has Normalized—What Next After TRED-HF?
Kasiakogias, A., Ragavan, A., & Halliday, B. P. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00636-8 · Cited by 5
Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy
Wang, M., Jia, L., Dai, X., & Zhang, X. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13621 · Cited by 10
Li, W., Wang, C., & Lu, Y. (2024) · Nano Research · doi:10.1007/s12274-024-6729-8 · Cited by 7
Bioactive-material-programmed CAR-T cell living drug for augmented immunotherapy against tumors
Huang, G., Tang, Z., Yin, T., Ma, A.-Q., Gong, H., Zhang, Y., Pan, H., & Cai, L. (2024) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2024.102022 · Cited by 9
Engineering Functional Particles to Modulate T Cell Responses
Li, Y., Li, S., Scheerstra, J. F., Patiño, T., van Hest, J. C. M., & Abdelmohsen, L. K. E. A. (2024) · Accounts of Materials Research · doi:10.1021/accountsmr.4c00105 · Cited by 6
Hypertension research 2024 update and perspectives: basic research
Kitada, K. (2024) · Hypertension Research · doi:10.1038/s41440-024-01878-2 · Cited by 7
LNP-mRNA delivers TNF-α antibody to deep cartilage and protects against osteoarthritis
Li, B., Cui, L., Kong, K., Pang, Y., Chen, Y., Zhang, S., Wang, F., Zhou, T., Hua, Y., Mi, C., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.156723 · Cited by 8
Engineered macrophages: an “Intelligent Repair” cellular machine for heart injury
Zhang, Z., Du, H., Gao, W., & Zhang, D. (2024) · Cell Regeneration · doi:10.1186/s13619-024-00209-7 · Cited by 5
Multivalent ionizable lipid-polypeptides for tumor-confined mRNA transfection
Zhao, X., Zhang, Y., Wang, X., Fu, Z.-M., Zhong, Z., & Deng, C. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.12.032 · Cited by 11
Synthetic receptor-based cell therapies for autoimmune diseases: an update
Lachota, M., & Zagożdżon, R. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.02.007 · Cited by 5
Gene- and Cell-Based Therapies in Cardiovascular Diseases
Zhang, C., Du, Z., Chen, R., Liu, X., & Li, D. (2025) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001707 · Cited by 5
Utilization of universal-targeting mSA2 CAR-T cells for the treatment of glioblastoma
Kourtesakis, A., Bailey, E., Chow, H. N. H., Rohdjeß, H., Mussnig, N., Agardy, D. A., Hoffmann, D. C. F., Chih, Y., Will, R. D., Kaulen, L. D., et al. (2025) · OncoImmunology · doi:10.1080/2162402x.2025.2518631 · Cited by 6
Knoedler, L., Herfeld, K., Schaefer, D., Diatta, F. H., Clune, J. E., Evans, B. G. A., Seu, M. Y., Kim, B., Alfertshofer, M. G., Schaschinger, T., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102240 · Cited by 6
Wang, J., Cai, L., Huang, G. H., Wang, C., Zhang, Z., & Xu, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28786 · Cited by 5
RNA technology and nanocarriers empowering in vivo chimeric antigen receptor therapy
Cai, J., Chen, S., Liu, Z., Li, H., Wang, P., Yang, F., Li, Y., Chen, K., Sun, M., & Qiu, M. (2024) · Immunology · doi:10.1111/imm.13861 · Cited by 7
Thermogenic T cells: a cell therapy for obesity?
Beier, U. H., Baker, D. J., & Baur, J. A. (2022) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00034.2022 · Cited by 5
Beydoun, N., & Feinstein, M. J. (2022) · Current Heart Failure Reports · doi:10.1007/s11897-022-00560-3 · Cited by 6
Immuno(T)herapy for age‐related diseases
Gabandé‐Rodríguez, E., Pfeiffer, M., & Mittelbrunn, M. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216301 · Cited by 5
Chen, Y., Huang, P., Niu, M., Tian, C., Zhang, T., & Peng, Z. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1159507 · Cited by 6
Chen, J., Jin, J., Jiang, J., & Wang, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1194884 · Cited by 5
KLIPP - a precision CRISPR approach to target structural variant junctions in cancerPreprint
Yang, H., Hulbatte, R. S., Kelleher, A. J., Gratsch, N., Wang, Y., Palmbos, P. L., & Ljungman, M. E. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.10.540176 · Cited by 6
Buggert, M., & Höglund, P. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13340 · Cited by 5
Melamed, J. R., Muscat-Rivera, J., Kegel, M., Chaboub, L. S., Perez‐Tremble, R., Bhalla, N. S., Ni, H., Sun, H., & Weissman, D. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.17.683125 · Cited by 10
Self-citationFibroblasts—The emerging therapeutic target of the cardiovascular system?
Asselberghs, S., Halder, M., Kramann, R., & Sluimer, J. C. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100072 · Cited by 4
Baliga, U. K., Yang, L., Ivanov, A. V., Schwartz, J. L., Jiang, F., Khor, E.-S., Das, D., Wainwright, L., & Yao, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167863 · Cited by 6
Precision Medicine: The Road to In Vivo Synthetic Therapeutic Agent
Miao, Y., Wang, Z., Song, F., Gao, R., Deng, Z. H., & Zhang, G. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202510183 · Cited by 6
Smart lipid nanoparticles: the chemistry driving targeted therapeutics
Abbrederis, N., Paloglou, D., & Astakhova, K. (2025) · Trends in Chemistry · doi:10.1016/j.trechm.2025.09.011 · Cited by 5
CAR-T cell therapy: A therapeutic strategy for cancer treatment
Sharif, S., Sharma, U., & Yadav, A. K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152430 · Cited by 5
Wu, J. R., Hernandez, Y., Canjels, A., Bailey, K. L., & Kwon, E. (2025) · Molecular Therapy: Nucleic Acids · doi:10.1016/j.omtn.2025.102817 · Cited by 4
Zhang, F., Zhao, B., Lu, K., Zeng, X., Wang, Z., Chen, W., Zhou, Y., Peng, J., & Zhao, L. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123954 · Cited by 4
Zhu, Y., Chen, C., Chen, J., Su, M., Huang, W., Liu, S., Yang, M., Mao, C., Shen, S., Yang, X. L., et al. (2026) · Advanced Materials · doi:10.1002/adma.202520493 · Cited by 7
Myeloid-lineage CAR knockin mice enable allogeneic immunotherapy for liver and lung fibrosis
Wang, M., Zhang, Y., Zhu, Q., Guan, L., Xun, Y., Liu, Y., Liu, Y., Hao, Y., Liu, S., Li, H., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.01.027 · Cited by 5
Patel, J., Azhar, M., Smith, R. H., Larochelle, A., Swenson, R. E., & Vasalatiy, O. V. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00608 · Cited by 7
Hao, L., Lu, J., & Xue, J. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.076420 · Cited by 5
Decoupling Physisorption from Chemisorption in Clickable Lipid Nanoparticles
Brysgel, T. V., Hood, E. D., Milosavljevic, A., Marzolini, N., Zamora, M. E., Wu, J., Shuvaev, V. V., Shuvaeva, T., Kegel, M., Muscat-Rivera, J., et al. (2026) · ACS Nanoscience Au · doi:10.1021/acsnanoscienceau.5c00170 · Cited by 4
Self-citationThe New Wave of Gene and Cell Therapies Across Diseases
Rieske, A., Grot, D., Tręda, C., Włodarczyk, A., Stoczyńska-Fidelus, E., Jaskólska, M., & Rieske, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051799 · Cited by 3
Chen, K., Wang, W., Lennon, A. C., McClure, R. A., Vuchkovska, A., Kelley, S. O., & Wang, Z. (2026) · Science Translational Medicine · doi:10.1126/scitranslmed.adx4097 · Cited by 4
Shi, C., Han, M.-S., Yang, H.-L., Zhao, X.-T., Zheng, Z., Wang, H., Fu, Z.-P., Dai, K., Zhao, K., Li, N., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.033 · Cited by 4
Kong, X., Cheng, R., Zhang, W., Lu, Y., Kan, Y., Fang, Y., Gao, J., Wang, J., & Hwang, K. C. (2026) · Drug Resistance Updates · doi:10.1016/j.drup.2026.101392 · Cited by 4
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 7
Spatio-temporal targeting of cardiac cells with lipid nanoparticles after myocardial infarction
Harper, R. L., Farrugia, G. E., Krstevski, C., Alexander, N., Raffaut, S. R., Harrison, T. I., Thomas, A. C., Kiriazis, H., Dogra, A., Vidallon, M. L. P., et al. (2026) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2026.100850 · Cited by 4
Li, X., Wu, B., Lu, X., Yang, J., Zhu, Y., Yamagata, H. M., Tong, E. C., Mitchell, M. J., & Han, X. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00043 · Cited by 5
Huang, C., Zuo, W., Xiao, J., Xiong, C., Zhu, L., Su, Y., & Zhan, M. (2026) · Materials Today Advances · doi:10.1016/j.mtadv.2026.100800 · Cited by 7
In vivo reprogramming of cytotoxic effector CD8 T cells via fractalkine-conjugated mRNA-LNPs
Corrigan, A. R., Ngiow, S. F., Statzu, M., Albertus, A., Pampena, M. B., Nordin, J. M. L., Carro, S. D., Harper, J. L., Stammen, R. L., Wood, J., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.aec3436 · Cited by 6
Self-citationEngineering immune cells for next-generation therapies
Han, M., Lou, J., Pan, M., Xu, S., Jiang, X., & Jing, W. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115012 · Cited by 5
Advances in RNA delivery to extrahepatic tissues and cells
Li, Z., Guo, S., & Huang, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115170 · Cited by 4
Du, J., Luo, Z., Xie, D., Chen, Y., Yang, M., Li, Q., Wang, L., Han, L., Zhang, Y., Li, H., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01765-w · Cited by 6
Zhao, Z., Deng, S., Wang, Q., Jia, C., & Yang, J. (2022) · Clinical Cancer Investigation Journal · doi:10.51847/0ozasxscb1 · Cited by 4
Hu, J., Zhong, L., Wang, Y., Hu, S., Zhang, L., & Tian, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00545-z · Cited by 4
Yang, Y., Li, X.-W., Chen, H., Tang, Q.-D., Li, Y., Xu, J., & Xie, J. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04080-x · Cited by 6
Seshire, A., Duan, Y., & Lang, K. (2024) · Handbook of experimental pharmacology · doi:10.1007/164_2024_723 · Cited by 4
Nucleic Acid Therapy for the Skin
Chai, A. C., Siegwart, D. J., & Wang, R. C. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.07.029 · Cited by 4
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.